Literature DB >> 18941729

[Adrenal tumors].

M K Walz1.   

Abstract

Adrenal tumors can be primary or secondary entities. Primary tumors are able to secrete hormones which may cause significant effects clinically. Typical tumor-related adrenal diseases are Conn's syndrome (hyperaldosteronism), Cushing's syndrome (hypercortisolism), and pheochromocytoma (catacholamine excess). Primary adrenal tumors are rarely malignant, but adrenocortical neoplasias show a relation between tumor size and rate of malignancy. Diagnostic methods for adrenal tumors include hormone tests and imaging. The first choice of treatment is surgical removal, today preferably by minimally invasive approaches.

Entities:  

Mesh:

Year:  2008        PMID: 18941729     DOI: 10.1007/s00104-008-1638-z

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  19 in total

1.  Posterior retroperitoneoscopic adrenalectomy: lessons learned within five years.

Authors:  M K Walz; K Peitgen; M V Walz; R Hoermann; B Saller; R M Giebler; F Jockenhövel; T Philipp; C E Broelsch; F W Eigler; K Mann
Journal:  World J Surg       Date:  2001-06       Impact factor: 3.352

Review 2.  Hormonal evaluation of the patient with an incidentally discovered adrenal mass.

Authors:  N S Ross; D C Aron
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

3.  Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients.

Authors:  Martin K Walz; Piero F Alesina; Frank A Wenger; Anastasios Deligiannis; Eduard Szuczik; Stephan Petersenn; Andreas Ommer; Harald Groeben; Klaus Peitgen; Onno E Janssen; Thomas Philipp; Hartmut P H Neumann; Kurt W Schmid; Klaus Mann
Journal:  Surgery       Date:  2006-12       Impact factor: 3.982

4.  On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes.

Authors:  H Hedeland; G Ostberg; B Hökfelt
Journal:  Acta Med Scand       Date:  1968-09

Review 5.  Selection of patients with adrenal incidentalomas for operation.

Authors:  E D Staren; R A Prinz
Journal:  Surg Clin North Am       Date:  1995-06       Impact factor: 2.741

6.  The changing clinical spectrum of primary aldosteronism.

Authors:  E L Bravo; R C Tarazi; H P Dustan; F M Fouad; S C Textor; R W Gifford; D G Vidt
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

7.  Functional results after endoscopic subtotal cortical-sparing adrenalectomy.

Authors:  Michael Brauckhoff; Phuong Nguyen Thanh; Oliver Gimm; Annett Bär; Katrin Brauckhoff; Henning Dralle
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

8.  The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses.

Authors:  William F Young; Hendrick du Plessis; Geoffrey B Thompson; Clive S Grant; David R Farley; Melanie L Richards; Dana Erickson; Adrian Vella; Anthony W Stanson; J Aidan Carney; Charles F Abboud; Paul C Carpenter
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 9.  Molecular markers and the pathogenesis of adrenocortical cancer.

Authors:  Patsy S H Soon; Kerrie L McDonald; Bruce G Robinson; Stan B Sidhu
Journal:  Oncologist       Date:  2008-05

10.  The role of adrenal venous sampling in the surgical management of primary aldosteronism.

Authors:  Antonio Toniato; Paolo Bernante; Gian Paolo Rossi; Maria Rosa Pelizzo
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282

View more
  2 in total

Review 1.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

2.  Differentiating Benign from Malignant Adrenocortical Tumors by a Single Morphological Parameter-a Clinicopathological Study on 837 Adrenocortical Neoplasias.

Authors:  Martin K Walz; Klaus A Metz; Sarah Theurer; Cathrin Myland; Pier F Alesina; Kurt W Schmid
Journal:  Indian J Surg Oncol       Date:  2020-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.